2.5 mg compounded semaglutide for Weight Loss - GLP-1 Medication Guide Semaglutide / Glycine – WP

In one double-blind, parallel-group, randomized, placebo-controlled trial, semaglutide was assessed as a weight-loss therapy in children 12-18 years of age with obesity (BMI in the 95 th percentile or higher) or who were overweight (BMI in the 85 th percentile or higher) but who had at least one comorbid condition related to their weight

Any use outside of these purposes is expressly prohibited

Immune System Support Your immune system relies on glutathione to function properly

If you take St Johns wort, talk with your doctor before taking Vyvanse

Successfully appealing a denial typically requires strong documentation from your clinician, outlining why the GLP-1 is medically necessary for your specific condition

Sources Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company July 23, 2026 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) National Library of Medicine April 13, 2026 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) National Library of Medicine May 22, 2026,